| Dr Gurjit Singh Randhawa, DDS, MDS | |
|
2229 Santa Clara Ave Ste E, Alameda, CA 94501-4409 | |
| (510) 521-3300 | |
| Not Available |
| Full Name | Dr Gurjit Singh Randhawa |
|---|---|
| Gender | Male |
| Speciality | Dentist |
| Location | 2229 Santa Clara Ave Ste E, Alameda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265640379 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 46941 (California) | Primary |
| 1223G0001X | Dentist - General Practice | 46941 (California) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gurjit Singh Randhawa, DDS, MDS 2229 Santa Clara Ave Ste E, Alameda, CA 94501-4409 Ph: (510) 521-3300 | Dr Gurjit Singh Randhawa, DDS, MDS 2229 Santa Clara Ave Ste E, Alameda, CA 94501-4409 Ph: (510) 521-3300 |
News Archive
The nation's first and only program linking paramedics in the field to patients' pre-existing health information - enabling emergency workers to make more informed treatment decisions and to transport patients to the most appropriate facility - has been recognized by the prestigious Computerworld Honors Program.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
The Intelligent Clinician's Guide to the DSM-5- explores all revisions to the latest version of the Diagnostic and Statistics Manual, and shows clinicians how they can best apply the strong points and shortcomings of psychiatry's most contentious resource.
EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doesn't contain any living cells at implantation. The vessel, that could be used as an "off the shelf" graft for kidney dialysis patients, performed well in a recent study with nonhuman primates.
› Verified 2 days ago
Dr. Cathy H. Pham, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 650-central Ave., Alameda, CA 94501 Phone: 510-769-1500 | |
Dr. Donald Melvan Brown, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 2238 Santa Clara Ave, Alameda, CA 94501 Phone: 510-522-3545 Fax: 510-522-2291 | |
William Blackmore Claussen, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2229 Santa Clara Ave, Alameda, CA 94501 Phone: 510-522-1945 Fax: 510-865-7346 | |
Dr. Gerald G Gelle, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2042 Central Ave, Alameda, CA 94501 Phone: 510-523-1995 Fax: 510-523-6155 | |
Teddy Belgica Eusebio, DDS Dentist Medicare: Medicare Enrolled Practice Location: 1242 Park St Ste A, Alameda, CA 94501 Phone: 510-865-6890 | |
Zahur-akhtar Subedar, Dentist Medicare: Not Enrolled in Medicare Practice Location: 1821 Santa Clara Ave, Alameda, CA 94501 Phone: 650-278-7982 | |
Zoya Tharani, Dentist Medicare: Not Enrolled in Medicare Practice Location: 2437 Lincoln Ave, Alameda, CA 94501 Phone: 510-522-2680 |